1
|
Nimmo F, Brown ME. The internal structure of Eris inferred from its spin and orbit evolution. Sci Adv 2023; 9:eadi9201. [PMID: 37967188 PMCID: PMC10651115 DOI: 10.1126/sciadv.adi9201] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Accepted: 10/17/2023] [Indexed: 11/17/2023]
Abstract
The large Kuiper Belt object Eris is tidally locked to its small companion Dysnomia. Recently obtained bounds on the mass of Dysnomia demonstrate that Eris must be unexpectedly dissipative for it to have despun over the age of the solar system. Here, we show that Eris must have differentiated into an ice shell and rocky core to explain the dissipation. We further demonstrate that Eris's ice shell must be convecting to be sufficiently dissipative, which distinguishes it from Pluto's conductive shell. The difference is likely due to Eris's apparent depletion in volatiles compared with Pluto, perhaps as the result of a more energetic impact.
Collapse
Affiliation(s)
- Francis Nimmo
- Department of Earth and Planetary Sciences, University of California Santa Cruz, Santa Cruz CA 95064, USA
| | - Michael E. Brown
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena CA 91125, USA
| |
Collapse
|
2
|
Trumbo SK, Brown ME. The distribution of CO 2 on Europa indicates an internal source of carbon. Science 2023; 381:1308-1311. [PMID: 37733851 DOI: 10.1126/science.adg4155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2022] [Accepted: 08/22/2023] [Indexed: 09/23/2023]
Abstract
Jupiter's moon Europa has a subsurface ocean, the chemistry of which is largely unknown. Carbon dioxide (CO2) has previously been detected on the surface of Europa, but it was not possible to determine whether it originated from subsurface ocean chemistry, was delivered by impacts, or was produced on the surface by radiation processing of impact-delivered material. We mapped the distribution of CO2 on Europa using observations obtained with the James Webb Space Telescope (JWST). We found a concentration of CO2 within Tara Regio, a recently resurfaced terrain. This indicates that the CO2 is derived from an internal carbon source. We propose that the CO2 formed in the internal ocean, although we cannot rule out formation on the surface through radiolytic conversion of ocean-derived organics or carbonates.
Collapse
Affiliation(s)
- Samantha K Trumbo
- Cornell Center for Astrophysics and Planetary Science, Cornell University, Ithaca, NY 14853, USA
| | - Michael E Brown
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| |
Collapse
|
3
|
Pejchal R, Cooper AB, Brown ME, Vásquez M, Krauland EM. Profiling the Biophysical Developability Properties of Common IgG1 Fc Effector Silencing Variants. Antibodies (Basel) 2023; 12:54. [PMID: 37753968 PMCID: PMC10526015 DOI: 10.3390/antib12030054] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Revised: 08/09/2023] [Accepted: 08/18/2023] [Indexed: 09/28/2023] Open
Abstract
Therapeutic antibodies represent the most significant modality in biologics, with around 150 approved drugs on the market. In addition to specific target binding mediated by the variable fragments (Fvs) of the heavy and light chains, antibodies possess effector functions through binding of the constant region (Fc) to Fcγ receptors (FcγR), which allow immune cells to attack and kill target cells using a variety of mechanisms. However, for some applications, including T-cell-engaging bispecifics, this effector function is typically undesired. Mutations within the lower hinge and the second constant domain (CH2) of IgG1 that comprise the FcγR binding interface reduce or eliminate effector function ("Fc silencing") while retaining binding to the neonatal Fc receptor (FcRn), important for normal antibody pharmacokinetics (PKs). Comprehensive profiling of biophysical developability properties would benefit the choice of constant region variants for development. Here, we produce a large panel of representative mutations previously described in the literature and in many cases in clinical or approved molecules, generate select combinations thereof, and characterize their binding and biophysical properties. We find that some commonly used CH2 mutations, including D265A and P331S, are effective in reducing binding to FcγR but significantly reduce stability, promoting aggregation, particularly under acidic conditions commonly employed in manufacturing. We highlight mutation sets that are particularly effective for eliminating Fc effector function with the retention of WT-like stability, including L234A, L235A, and S267K (LALA-S267K), L234A, L235E, and S267K (LALE-S267K), L234A, L235A, and P329A (LALA-P329A), and L234A, L235E, and P329G (LALE-P329G).
Collapse
Affiliation(s)
- Robert Pejchal
- Adimab LLC, Lebanon, NH 03766, USA; (M.E.B.); (M.V.); (E.M.K.)
| | | | | | | | | |
Collapse
|
4
|
Trumbo SK, Brown ME, Bockelée-Morvan D, de Pater I, Fouchet T, Wong MH, Cazaux S, Fletcher LN, de Kleer K, Lellouch E, Mura A, Poch O, Quirico E, Rodriguez-Ovalle P, Showalter MR, Tiscareno MS, Tosi F. Hydrogen peroxide at the poles of Ganymede. Sci Adv 2023; 9:eadg3724. [PMID: 37478185 PMCID: PMC10361591 DOI: 10.1126/sciadv.adg3724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Accepted: 06/21/2023] [Indexed: 07/23/2023]
Abstract
Ganymede is the only satellite in the solar system known to have an intrinsic magnetic field. Interactions between this field and the Jovian magnetosphere are expected to funnel most of the associated impinging charged particles, which radiolytically alter surface chemistry across the Jupiter system, to Ganymede's polar regions. Using observations obtained with JWST as part of the Early Release Science program exploring the Jupiter system, we report the discovery of hydrogen peroxide, a radiolysis product of water ice, specifically constrained to the high latitudes. This detection directly implies radiolytic modification of the polar caps by precipitation of Jovian charged particles along partially open field lines within Ganymede's magnetosphere. Stark contrasts between the spatial distribution of this polar hydrogen peroxide, those of Ganymede's other radiolytic oxidants, and that of hydrogen peroxide on neighboring Europa have important implications for understanding water-ice radiolysis throughout the solar system.
Collapse
Affiliation(s)
- Samantha K Trumbo
- Cornell Center for Astrophysics and Planetary Science, Cornell University, Ithaca, NY 14853, USA
| | - Michael E Brown
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | - Dominique Bockelée-Morvan
- LESIA, Observatoire de Paris, Université PSL, Sorbonne Université, Université Paris Cité, CNRS, Meudon 92195, France
| | - Imke de Pater
- Departments of Astronomy and of Earth and Planetary Science, University of California, Berkeley, CA 94720, USA
| | - Thierry Fouchet
- LESIA, Observatoire de Paris, Université PSL, Sorbonne Université, Université Paris Cité, CNRS, Meudon 92195, France
| | - Michael H Wong
- Center for Integrative Planetary Science, University of California, Berkeley, CA 94720-3411, USA
| | - Stéphanie Cazaux
- Faculty of Aerospace Engineering, Delft University of Technology, Delft, Netherlands
- Leiden Observatory, Leiden University, P.O. Box 9513, NL 2300 RA, Leiden, Netherlands
| | - Leigh N Fletcher
- School of Physics and Astronomy, University of Leicester, Leicester LE1 7RH, UK
| | - Katherine de Kleer
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | - Emmanuel Lellouch
- LESIA, Observatoire de Paris, Université PSL, Sorbonne Université, Université Paris Cité, CNRS, Meudon 92195, France
| | - Alessandro Mura
- Istituto Nazionale di AstroFisica-Istituto di Astrofisica e Planetologia Spaziali (INAF-IAPS), Rome, Italy
| | - Olivier Poch
- Université Grenoble Alpes, Centre National de la Recherche Scientifique (CNRS), Institut de Planétologie et d'Astrophysique de Grenoble (IPAG), Grenoble 38000, France
| | - Eric Quirico
- Université Grenoble Alpes, Centre National de la Recherche Scientifique (CNRS), Institut de Planétologie et d'Astrophysique de Grenoble (IPAG), Grenoble 38000, France
| | - Pablo Rodriguez-Ovalle
- LESIA, Observatoire de Paris, Université PSL, Sorbonne Université, Université Paris Cité, CNRS, Meudon 92195, France
| | | | | | - Federico Tosi
- Istituto Nazionale di AstroFisica-Istituto di Astrofisica e Planetologia Spaziali (INAF-IAPS), Rome, Italy
| |
Collapse
|
5
|
Mahjoub A, Altwegg K, Poston MJ, Rubin M, Hodyss R, Choukroun M, Ehlmann BL, Hänni N, Brown ME, Blacksberg J, Eiler JM, Hand KP. Complex organosulfur molecules on comet 67P: Evidence from the ROSINA measurements and insights from laboratory simulations. Sci Adv 2023; 9:eadh0394. [PMID: 37285429 DOI: 10.1126/sciadv.adh0394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Accepted: 05/01/2023] [Indexed: 06/09/2023]
Abstract
The ROSINA (Rosetta Orbiter Spectrometer for Ion and Neutral Analysis) instrument aboard the Rosetta mission revolutionized our understanding of cometary material composition. One of Rosetta's key findings is the complexity of the composition of comet 67P/Churyumov-Gerasimenko. Here, we used ROSINA data to analyze dust particles that were volatilized during a dust event in September 2016 and report the detection of large organosulfur species and an increase in the abundances of sulfurous species previously detected in the coma. Our data support the presence of complex sulfur-bearing organics on the surface of the comet. In addition, we conducted laboratory simulations that show that this material may have formed from chemical reactions that were initiated by the irradiation of mixed ices containing H2S. Our findings highlight the importance of sulfur chemistry in cometary and precometary materials and the possibility of characterizing organosulfur materials in other comets and small icy bodies using the James Webb Space Telescope.
Collapse
Affiliation(s)
- Ahmed Mahjoub
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
- Space Science Institute, 4765 Walnut St, Suite B, Boulder, CO 80301, USA
| | - Kathrin Altwegg
- Physikalisches Institut, University of Bern, Bern, Switzerland
| | | | - Martin Rubin
- Physikalisches Institut, University of Bern, Bern, Switzerland
| | - Robert Hodyss
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - Mathieu Choukroun
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - Bethany L Ehlmann
- Division of Planetary and Space Sciences, Caltech, Pasadena, CA 91125, USA
| | - Nora Hänni
- Physikalisches Institut, University of Bern, Bern, Switzerland
| | - Michael E Brown
- Division of Planetary and Space Sciences, Caltech, Pasadena, CA 91125, USA
| | - Jordana Blacksberg
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - John M Eiler
- Division of Planetary and Space Sciences, Caltech, Pasadena, CA 91125, USA
| | - Kevin P Hand
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| |
Collapse
|
6
|
Schmidt P, Narayan K, Li Y, Kaku CI, Brown ME, Champney E, Geoghegan JC, Vásquez M, Krauland EM, Yockachonis T, Bai S, Gunn BM, Cammarata A, Rubino CM, Ambrose P, Walker LM. Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers. Sci Transl Med 2023; 15:eadg2783. [PMID: 36947596 DOI: 10.1126/scitranslmed.adg2783] [Citation(s) in RCA: 11] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/24/2023]
Abstract
Multiple studies of vaccinated and convalescent cohorts have demonstrated that serum neutralizing antibody (nAb) titers correlate with protection against coronavirus disease 2019 (COVID-19). However, the induction of multiple layers of immunity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure has complicated the establishment of nAbs as a mechanistic correlate of protection (CoP) and hindered the definition of a protective nAb threshold. Here, we show that a half-life-extended monoclonal antibody (adintrevimab) provides about 50% protection against symptomatic COVID-19 in SARS-CoV-2-naïve adults at serum nAb titers on the order of 1:30. Vaccine modeling results support a similar 50% protective nAb threshold, suggesting that low titers of serum nAbs protect in both passive antibody prophylaxis and vaccination settings. Extrapolation of adintrevimab pharmacokinetic data suggests that protection against susceptible variants could be maintained for about 3 years. The results provide a benchmark for the selection of next-generation vaccine candidates and support the use of broad, long-acting monoclonal antibodies as alternatives or supplements to vaccination in high-risk populations.
Collapse
Affiliation(s)
| | | | - Yong Li
- Invivyd Inc., Waltham, MA 02451, USA
| | | | | | | | | | | | | | - Thomas Yockachonis
- Paul G. Allen School of Global Health, Washington State University, Pullman, WA 99164, USA
| | - Shuangyi Bai
- Paul G. Allen School of Global Health, Washington State University, Pullman, WA 99164, USA
| | - Bronwyn M Gunn
- Paul G. Allen School of Global Health, Washington State University, Pullman, WA 99164, USA
| | | | | | - Paul Ambrose
- Institute for Clinical Pharmacodynamics, Schenectady, NY 12305, USA
| | | |
Collapse
|
7
|
Liu CY, Ahonen CL, Brown ME, Zhou L, Welin M, Krauland EM, Pejchal R, Widboom PF, Battles MB. Structure-based engineering of a novel CD3ε-targeting antibody for reduced polyreactivity. MAbs 2023; 15:2189974. [PMID: 36991534 PMCID: PMC10072072 DOI: 10.1080/19420862.2023.2189974] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/31/2023] Open
Abstract
Bispecific antibodies continue to represent a growth area for antibody therapeutics, with roughly a third of molecules in clinical development being T-cell engagers that use an anti-CD3 binding arm. CD3 antibodies possessing cross-reactivity with cynomolgus monkey typically recognize a highly electronegative linear epitope at the extreme N-terminus of CD3 epsilon (CD3ε). Such antibodies have high isoelectric points and display problematic polyreactivity (correlated with poor pharmacokinetics for monospecific antibodies). Using insights from the crystal structure of anti-Hu/Cy CD3 antibody ADI-26906 in complex with CD3ε and antibody engineering using a yeast-based platform, we have derived high-affinity CD3 antibody variants with very low polyreactivity and significantly improved biophysical developability. Comparison of these variants with CD3 antibodies in the clinic (as part of bi- or multi-specifics) shows that affinity for CD3 is correlated with polyreactivity. Our engineered CD3 antibodies break this correlation, forming a broad affinity range with no to low polyreactivity. Such antibodies will enable bispecifics with improved pharmacokinetic and safety profiles and suggest engineering solutions that will benefit the large and growing sector of T-cell engagers.
Collapse
|
8
|
Abstract
Previous research on workplace conflict has focused on disagreements about work tasks, processes, and personal relationships. However, conflicts often involve matters of right and wrong; yet, ethical conflict is notably absent from the literature. Informed by moral convictions theory, we introduce the construct of ethical conflict, create and validate a measure of it, and explore its unique effects on workplace outcomes. Ultimately, we find that ethical conflict is a double-edged sword: It is negatively associated with team dynamics (i.e., decreased satisfaction with group, group viability, group cohesion, group psychological safety; increased negative emotions; and perceived goal difficulty) as well as group performance on a non-ethics-related task, but positively related to moral cognition (i.e., moral awareness and moral identity accessibility) and elaboration of information and perspectives during group ethical decision making. Overall, our studies provide a conceptual and empirical foundation for the future research on ethical conflict. (PsycInfo Database Record (c) 2021 APA, all rights reserved).
Collapse
Affiliation(s)
- Michael E Brown
- Department of Management, Black School of Business, The Behrend College, Pennsylvania State University-Erie
| | | | | |
Collapse
|
9
|
Rappazzo CG, Tse LV, Kaku CI, Wrapp D, Sakharkar M, Huang D, Deveau LM, Yockachonis TJ, Herbert AS, Battles MB, O'Brien CM, Brown ME, Geoghegan JC, Belk J, Peng L, Yang L, Hou Y, Scobey TD, Burton DR, Nemazee D, Dye JM, Voss JE, Gunn BM, McLellan JS, Baric RS, Gralinski LE, Walker LM. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science 2021; 371:823-829. [PMID: 33495307 PMCID: PMC7963221 DOI: 10.1126/science.abf4830] [Citation(s) in RCA: 220] [Impact Index Per Article: 73.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2020] [Accepted: 01/19/2021] [Indexed: 12/12/2022]
Abstract
The recurrent zoonotic spillover of coronaviruses (CoVs) into the human population underscores the need for broadly active countermeasures. We employed a directed evolution approach to engineer three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies for enhanced neutralization breadth and potency. One of the affinity-matured variants, ADG-2, displays strong binding activity to a large panel of sarbecovirus receptor binding domains and neutralizes representative epidemic sarbecoviruses with high potency. Structural and biochemical studies demonstrate that ADG-2 employs a distinct angle of approach to recognize a highly conserved epitope that overlaps the receptor binding site. In immunocompetent mouse models of SARS and COVID-19, prophylactic administration of ADG-2 provided complete protection against respiratory burden, viral replication in the lungs, and lung pathology. Altogether, ADG-2 represents a promising broad-spectrum therapeutic candidate against clade 1 sarbecoviruses.
Collapse
MESH Headings
- Angiotensin-Converting Enzyme 2/metabolism
- Animals
- Antibodies, Monoclonal/genetics
- Antibodies, Monoclonal/immunology
- Antibodies, Monoclonal/metabolism
- Antibodies, Viral/genetics
- Antibodies, Viral/immunology
- Antibodies, Viral/metabolism
- Antibody Affinity
- Betacoronavirus/immunology
- Binding Sites
- Binding Sites, Antibody
- Broadly Neutralizing Antibodies/genetics
- Broadly Neutralizing Antibodies/immunology
- Broadly Neutralizing Antibodies/metabolism
- COVID-19/prevention & control
- COVID-19/therapy
- Cell Surface Display Techniques
- Directed Molecular Evolution
- Epitopes/immunology
- Humans
- Immunization, Passive
- Immunoglobulin Fc Fragments/immunology
- Mice, Inbred BALB C
- Protein Domains
- Protein Engineering
- Receptors, Coronavirus/metabolism
- Severe acute respiratory syndrome-related coronavirus/immunology
- SARS-CoV-2/immunology
- Severe Acute Respiratory Syndrome/immunology
- Severe Acute Respiratory Syndrome/prevention & control
- Severe Acute Respiratory Syndrome/therapy
- Spike Glycoprotein, Coronavirus/immunology
- Spike Glycoprotein, Coronavirus/metabolism
- COVID-19 Serotherapy
- Mice
Collapse
Affiliation(s)
| | - Longping V Tse
- Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | | | - Daniel Wrapp
- Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA
| | | | - Deli Huang
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | | | - Thomas J Yockachonis
- Paul G. Allen School of Global Animal Health, Washington State University, Pullman, WA 99164, USA
| | - Andrew S Herbert
- U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA
- The Geneva Foundation, Tacoma, WA 98402, USA
| | | | - Cecilia M O'Brien
- U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA
- The Geneva Foundation, Tacoma, WA 98402, USA
| | | | | | | | - Linghang Peng
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Linlin Yang
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Yixuan Hou
- Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Trevor D Scobey
- Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Dennis R Burton
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA
- IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA
- Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA
- Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA 02139, USA
| | - David Nemazee
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - John M Dye
- U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA
| | - James E Voss
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Bronwyn M Gunn
- Paul G. Allen School of Global Animal Health, Washington State University, Pullman, WA 99164, USA
| | - Jason S McLellan
- Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA
| | - Ralph S Baric
- Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- Departments of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Lisa E Gralinski
- Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
| | - Laura M Walker
- Adimab, LLC, Lebanon, NH 03766, USA.
- Adagio Therapeutics, Inc., Waltham, MA 02451, USA
| |
Collapse
|
10
|
Rappazzo CG, Tse LV, Kaku CI, Wrapp D, Sakharkar M, Huang D, Deveau LM, Yockachonis TJ, Herbert AS, Battles MB, O’Brien CM, Brown ME, Geoghegan JC, Belk J, Peng L, Yang L, Scobey TD, Burton DR, Nemazee D, Dye JM, Voss JE, Gunn BM, McLellan JS, Baric RS, Gralinski LE, Walker LM. An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19. bioRxiv 2020:2020.11.17.385500. [PMID: 33236009 PMCID: PMC7685319 DOI: 10.1101/2020.11.17.385500] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The recurrent zoonotic spillover of coronaviruses (CoVs) into the human population underscores the need for broadly active countermeasures. Here, we employed a directed evolution approach to engineer three SARS-CoV-2 antibodies for enhanced neutralization breadth and potency. One of the affinity-matured variants, ADG-2, displays strong binding activity to a large panel of sarbecovirus receptor binding domains (RBDs) and neutralizes representative epidemic sarbecoviruses with remarkable potency. Structural and biochemical studies demonstrate that ADG-2 employs a unique angle of approach to recognize a highly conserved epitope overlapping the receptor binding site. In murine models of SARS-CoV and SARS-CoV-2 infection, passive transfer of ADG-2 provided complete protection against respiratory burden, viral replication in the lungs, and lung pathology. Altogether, ADG-2 represents a promising broad-spectrum therapeutic candidate for the treatment and prevention of SARS-CoV-2 and future emerging SARS-like CoVs.
Collapse
Affiliation(s)
| | - Longping V. Tse
- Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | | | - Daniel Wrapp
- Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA
| | | | - Deli Huang
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | | | - Thomas J. Yockachonis
- Paul G. Allen School of Global Animal Health, Washington State University, Pullman, WA 99164, USA
| | - Andrew S. Herbert
- U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA
- The Geneva Foundation, 917 Pacific Avenue, Tacoma, WA 98402, USA
| | | | - Cecilia M. O’Brien
- U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA
- The Geneva Foundation, 917 Pacific Avenue, Tacoma, WA 98402, USA
| | | | | | | | - Linghang Peng
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Linlin Yang
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Trevor D. Scobey
- Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Dennis R. Burton
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA
- IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA
- Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA
- Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA 02139, USA
| | - David Nemazee
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - John M. Dye
- U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA
| | - James E. Voss
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Bronwyn M. Gunn
- Paul G. Allen School of Global Animal Health, Washington State University, Pullman, WA 99164, USA
| | - Jason S. McLellan
- Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA
| | - Ralph S. Baric
- Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
- Departments of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Lisa E. Gralinski
- Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Laura M. Walker
- Adimab LLC, Lebanon, NH 03766, USA
- Adagio Therapeutics, Inc., Waltham, MA 02451, USA
| |
Collapse
|
11
|
Brown ME, Bedinger D, Lilov A, Rathanaswami P, Vásquez M, Durand S, Wallace-Moyer I, Zhong L, Nett JH, Burnina I, Caffry I, Lynaugh H, Sinclair M, Sun T, Bukowski J, Xu Y, Abdiche YN. Assessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors. PLoS One 2020; 15:e0229206. [PMID: 32134960 PMCID: PMC7058304 DOI: 10.1371/journal.pone.0229206] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2019] [Accepted: 01/31/2020] [Indexed: 12/21/2022] Open
Abstract
Here we describe an industry-wide collaboration aimed at assessing the binding properties of a comprehensive panel of monoclonal antibodies (mAbs) against programmed cell death protein 1 (PD-1), an important checkpoint protein in cancer immunotherapy and validated therapeutic target, with well over thirty unique mAbs either in clinical development or market-approved in the United States, the European Union or China. The binding kinetics of the PD-1/mAb interactions were measured by surface plasmon resonance (SPR) using a Carterra LSA instrument and the results were compared to data collected on a Biacore 8K. The effect of chip type on the SPR-derived binding rate constants and affinities were explored and the results compared with solution affinities from Meso Scale Discovery (MSD) and Kinetic Exclusion Assay (KinExA) experiments. When using flat chip types, the LSA and 8K platforms yielded near-identical kinetic rate and affinity constants that matched solution phase values more closely than those produced on 3D-hydrogels. Of the anti-PD-1 mAbs tested, which included a portion of those known to be in clinical development or approved, the affinities spanned from single digit picomolar to nearly 425 nM, challenging the dynamic range of our methods. The LSA instrument was also used to perform epitope binning and ligand competition studies which revealed over ten unique competitive binding profiles within this group of mAbs.
Collapse
Affiliation(s)
- Michael E. Brown
- Department of Protein Analytics, Adimab, Lebanon, NH, United States of America
- * E-mail: (MEB); (YNA)
| | | | - Asparouh Lilov
- Department of Protein Analytics, Adimab, Lebanon, NH, United States of America
| | | | - Maximiliano Vásquez
- Department of Computational Biology, Adimab, Palo Alto, CA, United States of America
| | - Stéphanie Durand
- Department of High Throughput Expression, Adimab, Lebanon, NH, United States of America
| | - Ian Wallace-Moyer
- Department of High Throughput Expression, Adimab, Lebanon, NH, United States of America
| | - Lihui Zhong
- Department of High Throughput Expression, Adimab, Lebanon, NH, United States of America
| | - Juergen H. Nett
- Department of High Throughput Expression, Adimab, Lebanon, NH, United States of America
| | - Irina Burnina
- Department of Protein Analytics, Adimab, Lebanon, NH, United States of America
| | - Isabelle Caffry
- Department of Protein Analytics, Adimab, Lebanon, NH, United States of America
| | - Heather Lynaugh
- Department of Protein Analytics, Adimab, Lebanon, NH, United States of America
| | - Melanie Sinclair
- Department of Protein Analytics, Adimab, Lebanon, NH, United States of America
| | - Tingwan Sun
- Department of Protein Analytics, Adimab, Lebanon, NH, United States of America
| | - John Bukowski
- Department of Antibody Discovery, Adimab, Lebanon, NH, United States of America
| | - Yingda Xu
- Department of Protein Analytics, Adimab, Lebanon, NH, United States of America
| | | |
Collapse
|
12
|
Nejati M, Brown ME, Shafaei A, Seet PS. Employees’ perceptions of corporate social responsibility and ethical leadership: are they uniquely related to turnover intention? SRJ 2020. [DOI: 10.1108/srj-08-2019-0276] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Purpose
The purpose of this study is to investigate the simultaneous effect of ethical leadership (EL) and corporate social responsibility (CSR) on employees’ turnover intention and examine the mediating mechanism in these relationships.
Design/methodology/approach
The authors conducted a field study of 851 employees across a variety of industries. This study applied partial least squares structural equation modelling for hypothesis testing.
Findings
The results show that employees’ perceptions of CSR as well as EL are both uniquely and negatively related to turnover intention. The authors also found that employees’ job satisfaction but not commitment, mediates these relationships.
Research limitations/implications
This study answers the recent call (Schminke and Sheridan, 2017) for ethics researchers to put competing explanations to the test to determine their relative importance. Research limitations have been discussed in the paper.
Social implications
Through providing empirical support for the positive impact of CSR and EL on employee-related outcomes and creating a decent and empowering work environment, this study provides further support for CSR and EL. As CSR and EL require accountability, responsible management and addressing societal well-being of stakeholders, this study can contribute to the United Nations sustainable development goals.
Originality/value
Previous research has found that both employees’ perceptions of supervisory EL and CSR are negatively related to employees’ turnover intentions. Yet, researchers know little about their relative importance because these relationships have not been adequately examined simultaneously.
Collapse
|
13
|
Abstract
The potential habitability of Europa's subsurface ocean depends on its chemical composition, which may be reflected in that of Europa's geologically young surface. Investigations using Galileo Near-Infrared Mapping Spectrometer data led to the prevailing view that Europa's endogenous units are rich in sulfate salts. However, recent ground-based infrared observations have suggested that, while regions experiencing sulfur radiolysis may contain sulfate salts, Europa's more pristine endogenous material may reflect a chloride-dominated composition. Chlorides have no identifying spectral features at infrared wavelengths, but develop distinct visible-wavelength absorptions under irradiation, like that experienced on the surface of Europa. Using spectra obtained with the Hubble Space Telescope, we present the detection of a 450-nm absorption indicative of irradiated sodium chloride on the surface. The feature correlates with geologically disrupted chaos terrain, suggesting an interior source. The presence of endogenous sodium chloride on the surface of Europa has important implications for our understanding of its subsurface chemistry.
Collapse
Affiliation(s)
- Samantha K Trumbo
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | - Michael E Brown
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | - Kevin P Hand
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| |
Collapse
|
14
|
Steglich CS, Brown ME, Mitchell EM, Millen M, Rehorek SJ. Isolation and characterization of abundantly-expressed cDNAs from the Harderian gland of the garter snake (Thamnophis sirtalis: Colubridae). Comp Biochem Physiol A Mol Integr Physiol 2019; 235:22-28. [PMID: 31100465 DOI: 10.1016/j.cbpa.2019.05.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2019] [Revised: 03/27/2019] [Accepted: 05/02/2019] [Indexed: 10/26/2022]
Abstract
The Harderian gland (HG) is an orbital structure whose proteinaceous secretions pass through the nasolacrimal duct to the vomeronasal organ (VNO). Though these three structures occur in many tetrapod vertebrates, the garter snake (Thamnophis sirtalis) is one of the few vertebrates in which the passage of the proteinaceous secretions have been experimentally shown. Secreted proteins from the HG may function as transporters for chemical signals to the VNO epithelium. To investigate the proteins being produced by the HG of the garter snake, cDNA libraries were constructed from HG mRNA, and several individual cDNAs were analyzed by sequencing, RT-qPCR, and PCR on genomic DNA. Two of the three cDNAs that were characterized are abundantly expressed only in the Harderian gland and contain putative signal sequences for secretion, which makes them candidates for transporter proteins secreted from the HG. One is a member of the large lipocalin family of proteins, based on its similarity to other members of that protein family. Many lipocalins are binding/carrier proteins for a variety of ligands. The other is a family of proteins, with five members identified so far, all of unknown structure and function and present in the garter snake genome but not in other squamate genomes.
Collapse
Affiliation(s)
- Carolyn S Steglich
- Department of Biology, Slippery Rock University, Slippery Rock, PA 16057, USA.
| | - Michael E Brown
- Department of Biology, Slippery Rock University, Slippery Rock, PA 16057, USA
| | - Elaina M Mitchell
- Department of Biology, Slippery Rock University, Slippery Rock, PA 16057, USA
| | - Michelle Millen
- Department of Biology, Slippery Rock University, Slippery Rock, PA 16057, USA
| | - Susan J Rehorek
- Department of Biology, Slippery Rock University, Slippery Rock, PA 16057, USA
| |
Collapse
|
15
|
Rogers TF, Goodwin EC, Briney B, Sok D, Beutler N, Strubel A, Nedellec R, Le K, Brown ME, Burton DR, Walker LM. Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors. Sci Immunol 2017; 2:eaan6809. [PMID: 28821561 PMCID: PMC5892203 DOI: 10.1126/sciimmunol.aan6809] [Citation(s) in RCA: 77] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2017] [Revised: 06/02/2017] [Accepted: 07/24/2017] [Indexed: 12/14/2022]
Abstract
Zika virus (ZIKV) shares a high degree of homology with dengue virus (DENV), suggesting that preexisting immunity to DENV could affect immune responses to ZIKV. We have tracked the evolution of ZIKV-induced B cell responses in three DENV-experienced donors. The acute antibody (plasmablast) responses were characterized by relatively high somatic hypermutation and a bias toward DENV binding and neutralization, implying the early activation of DENV clones. A DENV-naïve donor in contrast showed a classical primary plasmablast response. Five months after infection, the DENV-experienced donors developed potent type-specific ZIKV neutralizing antibody responses in addition to DENV cross-reactive responses. Because cross-reactive responses were poorly neutralizing and associated with enhanced ZIKV infection in vitro, preexisting DENV immunity could negatively affect protective antibody responses to ZIKV. The observed effects are epitope-dependent, suggesting that a ZIKV vaccine should be carefully designed for DENV-seropositive populations.
Collapse
Affiliation(s)
- Thomas F Rogers
- Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA
| | | | - Bryan Briney
- Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA
| | - Devin Sok
- Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA
| | - Nathan Beutler
- Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA
| | - Alexander Strubel
- Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA
| | - Rebecca Nedellec
- Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA
| | - Khoa Le
- Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA
| | | | - Dennis R Burton
- Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA.
- Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA
| | | |
Collapse
|
16
|
Hough LH, Brown ME. Labeling of neuronal morphology using custom diolistic techniques. J Neurosci Methods 2017; 282:43-51. [PMID: 28274738 DOI: 10.1016/j.jneumeth.2017.03.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2016] [Revised: 03/01/2017] [Accepted: 03/03/2017] [Indexed: 11/19/2022]
Abstract
BACKGROUND Diolistic labeling is increasingly utilized in neuroscience as an efficient, reproducible method for visualization of neuronal morphology. The use of lipophilic carbocyanine dyes, combined with particle-mediated biolistic delivery allows for non-toxic fluorescent labeling of multiple neurons in both living and fixed tissue. Since first described, this labeling method has been modified to fit a variety of research goals and laboratory settings. NEW METHOD Diolistic labeling has traditionally relied on commercially available devices for the propulsion of coated micro-particles into tissue sections. Recently, laboratory built biolistic devices have been developed which allow for increased availability and customization. Here, we discuss a custom biolistic device and provide a detailed protocol for its use. RESULTS Using custom diolistic labeling we have characterized alterations in neuronal morphology of the lateral/dentate nucleus of the rat cerebellum. Comparisons were made in developing rat pups exposed to abnormally high levels of 5-methyloxytryptamine (5-MT) pre-and postnatally. Using quantitative software; dendritic morphology, architecture, and synaptic connections, were analyzed. COMPARISON WITH EXISTING METHOD(S) The rapid nature of custom diolistics coupled with passive diffusion of dyes and compatibility with confocal microscopy, provides an unparalleled opportunity to examine features of neuronal cells at high spatial resolution in a three-dimensional tissue environment. CONCLUSIONS While decreasing the associated costs, the laboratory-built device also overcomes many of the obstacles associated with traditional morphological labeling, to allow for reliable and reproducible neuronal labeling. The versatility of this method allows for its adaptation to a variety of laboratory settings and neuroscience related research goals.
Collapse
Affiliation(s)
- Lyon H Hough
- Department of Biomedical Sciences, Missouri State University, Springfield, MO 65897, USA.
| | - Michael E Brown
- Department of Pathology, Saint Louis University School of Medicine, St. Louis, MO, USA
| |
Collapse
|
17
|
Paoletti C, Regan MM, Liu MC, Marcom PK, Hart LL, Smith JW, Tedesco KL, Amir E, Krop IE, DeMichele AM, Goodwin PJ, Block M, Aung K, Cannell EM, Darga EP, Baratta PJ, Brown ME, McCormack RT, Hayes DF. Abstract P1-01-01: Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-01-01] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Only half of hormone receptor positive (HR+) metastatic breast cancer (MBC) patients (pts) benefit from endocrine therapy (ET). Circulating tumor cells (CTC) are prognostic in pts with MBC using CellSearch® technology. The CTC-endocrine therapy index (CTC-ETI) provides semi-quantitative analyses of CTC-ER (estrogen receptor), BCL2, HER2, and Ki67 expression. We hypothesized that CTC-ETI high (elevated CTC number and/or low expression of ER and BCL2, and high expression of HER2 and Ki-67) might predict resistance to ET in a prospective, multi-institutional clinical trial: COMETI-P2-2012.0 (NCT01701050).
Methods: 121 pts with ER+, HER2 negative (-), and progressive MBC after one or more lines of ET or within 12 months (mos) of completing adjuvant ET, who were initiating a new ET, were enrolled after informed consent. CTC and CTC-ETI were determined as previously reported (Paoletti C et al, CCR 2015) at baseline (BL), 1, 2, 3, and 12 mos, and/or at the time of progression. Imaging was performed every 3 mos. Association of CTC levels and CTC-ETI with patient outcomes (progression free survival (PFS); rapid progression (RP) defined as progression within 3 mos) was assessed using logrank and Fisher's exact tests. Trial design estimated 85 PFS and 51 RP events, providing >90% power (2-sided a=0.05); pts with unsuccessful BL CTC-ETI or ineligible were unevaluable. Only baseline (BL) data are reported in this abstract.
Results: 32% of enrolled pts had progression within 12 mos of completing adjuvant ET, whereas 40%, 20%, and 8% had 1, 2, ≥3 lines of ET for MBC. CTC-ETI was successfully determined in 93% of pts (90% CI, 88% to 97%). CTC were ≥5 CTC/7.5 ml whole blood in 37/108 (34%) pts evaluable for clinical validity. Elevated CTC was associated with worse PFS (median (m) PFS: 3.3 vs. 5.9 mos; P<0.01). Low, intermediate, and high CTC-ETI were observed in 75 (69%), 6 (6%), and 27 (25%) pts, respectively. CTC-ETI was associated with PFS (logrank P<0.01): pts with low, intermediate, and high CTC-ETI had mPFS of 5.7, 8.5, and 2.8 mos, respectively. In the 96 pts eligible for determination, elevated CTC was associated with RP, (65.6% vs. 42.2%; P=0.05) as was CTC-ETI (P=0.003): 79.2% (95% CI, 57.8% to 92.9%) of pts with high CTC-ETI had RP versus 41.2% (95% CI, 29.4% to 53.8%) with low CTC-ETI; in the small group with intermediate CTC-ETI 1 of 4 pts (25%) had RP.
Conclusions: In this multi-institutional, prospective study, CTC-ETI was accurately determined, confirming the previously established analytical validity of the assay, meeting the primary objective of the trial. Elevated CTC and CTC-ETI high compared to low were associated with poor outcomes to ET. CTC-ETI distribution resulted in a small number of patients assigned to the intermediate group, restricting our ability to associate this group with outcomes. These results suggest that CTC-biomarker phenotype and enumeration have clinical validity. CTC-ETI may identify ER+ HER2– MBC pts who are unlikely to benefit from ET and might be better treated with ET in combination with other therapies or proceed to chemotherapy. Further analyses including CTC-ETI at serial time points during ET are planned.
Citation Format: Paoletti C, Regan MM, Liu MC, Marcom PK, Hart LL, Smith II JW, Tedesco KL, Amir E, Krop IE, DeMichele AM, Goodwin PJ, Block M, Aung K, Cannell EM, Darga EP, Baratta PJ, Brown ME, McCormack RT, Hayes DF. Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-01-01.
Collapse
Affiliation(s)
- C Paoletti
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - MM Regan
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - MC Liu
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - PK Marcom
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - LL Hart
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - JW Smith
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - KL Tedesco
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - E Amir
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - IE Krop
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - AM DeMichele
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - PJ Goodwin
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - M Block
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - K Aung
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - EM Cannell
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - EP Darga
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - PJ Baratta
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - ME Brown
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - RT McCormack
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| | - DF Hayes
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University, Duke Cancer Center, Durham, NC; Florida Cancer Specialist (South Division), Fort Myers, FL; Northwest Cancer Specialists, Portland, OR; New York Oncology Hematology, US Oncology Research, Albany, NY; Princess Margaret Hospital, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Mt. Sinai Hospital-Toronto, Toronto, ON, Canada; Nebraska Cancer Specialists, Omaha, NE; Janssen Pharmaceuticals, Inc., Raritan, NJ
| |
Collapse
|
18
|
Belvitch P, Dudek S, Brown ME, Garcia JG. ID: 131: ACTIN RELATED PROTEIN 2/3 COMPLEX REGULATES ACTIN MEMBRANE STRUCTURES TO DETERMINE ENDOTHELIAL BARRIER FUNCTION. J Investig Med 2016. [DOI: 10.1136/jim-2016-000120.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
RationaleDisruption of the pulmonary endothelial barrier is a hallmark feature of sepsis and acute lung injury/ARDS. Cytoskeletal structures such as the peripheral protrusive structures lamellipodia and filopodia are hypothesized to be important determinants of endothelial barrier function. The actin related protein 2/3 complex (Arp 2/3) is a key regulator of branched actin polymerization and may play a role in the determination and recovery of endothelial cell (EC) barrier integrity. In the current study, we make detailed observations of actin structures and membrane formations in the presence of a specific Arp 2/3 inhibitor. In addition, we study the subcellular co-localization of Arp 2/3 and cortactin, another known protein regulator of peripheral actin dynamics.MethodsCultured human lung microvascular endothelial cells (HLMVEC) were subjected to pre-treatment with the specific Arp 2/3 inhibitor (CK-666 50 µM) or vehicle (DMSO) x 1 hour. Cells were then treated with barrier enhancing sphingosine-1-phosphate (S1P 1 µM) or barrier disruptive thrombin (1 U/ml) and fixed at various time points (2–90 min) for subsequent imaging. Cells were permeabilized and treated with far-red phalloidin to stain actin, an anti-cortactin-GFP mAb as well as DAPI and imaged by confocal microscopy. Peripheral actin formations and associated membrane lamellipodia and filopodia were then measured and characterized. Additionally, the co-localization of Arp 2/3 and cortactin was determined.ResultsArp 2/3 inhibition markedly reduced lamellipodia formation in response to S1P (1 µM) over a range of time points (2–30 min). Lamellipodia depth was decreased in Arp 2/3 inhibited cells compared to control both at baseline (1.825 +/− 0.407 µM) vs. (2.545 +/− 0.459 µM) and following 30 min treatment with 1 µM S1P (1.534 +/− 0.365 µM) vs. (2.090 +/− 0.356 µM). Similarly, filopodia were shorter following Arp 2/3 inhibition (2.392 +/− 0.393 µM) vs. control (2.753 +/− 0.274 µM). Robust colocalization of Arp 2/3 and cortactin was observed very early (2–5 min) following S1P (1 µM) treatment in vehicle treated cells but was attenuated in the presence of the Arp 2/3 inhibitor. Following thrombin treatment (1 U/ml), peripheral lamellipodia were observed during the barrier recovery phase (30–60 min) but were markedly reduced following Arp 2/3 inhibition along with the persistence of intercellular gaps.ConclusionThese results further demonstrate the importance of the Arp 2/3 complex in pulmonary endothelial barrier integrity and recovery. These experiments also serve to relate the concept of altered peripheral actin and membrane dynamics leading to changes in EC barrier function.
Collapse
|
19
|
Paoletti C, Cani AK, Aung K, Darga EP, Cannell EM, Hovelson DH, Yazdani M, Blevins AR, Tokudome N, Larios JM, Thomas DG, Brown ME, Gersch C, Schott AF, Robinson DR, Chinnaiyan AM, Bischoff F, Hayes DF, Rae JM, Tomlins SA. Abstract P2-02-19: Somatic genetic profiling of circulating tumor cells (CTC) in metastatic breast cancer (MBC) patients. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-02-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Somatic mutations, including those in TP53, PIK3CA, and estrogen receptor alpha (ESR1), are key to the biology of cancer and response to therapy. Recently, somatic cancer-associated mutations have been identified in circulating cell free plasma tumor DNA (ptDNA). Less is known about the mutation profile of DNA extracted from CTC (CTC-DNA). Since CTC-DNA provides mutational information of single cells, we hypothesize CTC-DNA will complement ptDNA to give greater insight into tumor heterogeneity.
Methods: Patients with ER positive MBC who were enrolled in the Mi CTC-ONCOSEQ, a companion trial to Mi-ONCOSEQ (the Michigan Oncology Sequencing Program), and who had ≥5CTC/7.5 ml whole blood were included. CTC were enriched from white blood cells (WBC) with CellSearch© (CXC kit). CTC and WBC were then purified using DEPArrayTM. DNA from individual CTC and WBC was isolated and subjected to whole genomic amplification (Ampli 1TM WGA). Genetic analysis was performed on individual CTC, pooled CTC and pooled WBC DNA by multiplexed PCR based targeted next generation sequencing (NGS) using the Oncomine Comprehensive Panel (targeting ∼130 onco- and tumor suppressor genes) and the Ion Torrent Proton. All patients had exome sequencing performed on research biopsies of metastases using an Illumina HiSeq 2500 platform.
Results: This pilot study was conducted using high quality DNA from two patients assessed to date. Both patients had lobular carcinoma and as expected harbored somatic, deleterious CDH1 (E-cadherin) mutations (frameshift and non-sense) in both research biopsy and CTC-DNA. These data supported our approach. Patient #1 was TP53 wild type in her research biopsy, but multiple CTC harbored somatic TP53 frame-shift mutations (Table). Patient #2 harbored an ESR1 Y537S mutation in her research biopsy. However, only 4 of 7 CTC also harbored this somatic, heterozygous mutation.
Prioritized mutations in CTCPt#Cell Type (CTC vs WBC), numberGeneMutationVariant fraction (expected 1=homozygous; 0.5=heterozygous)Found in research biopsy?1CTC_A2CDH1p.I584fs1YES CTC_A4 1 CTC_A7 0.54 CTC_pool* 0.74 WBC_pool 0 CTC_A2TP53p.152_156del1NO CTC_A4 1 CTC_A7 0.51 CTC_pool* 0.88 WBC_pool 0 2CTC_A9ESR1p.Y537S0.52YES CTC_D1 0.34 CTC_D2 0.46 CTC_D6 0.65 CTC_pool* 0.35 WBC_pool 0 CTC_A12 0 CTC_D3 0 CTC_D7 0 CTC_A12CDH1p.Q641X1YES CTC_A9 1 CTC_D1 1 CTC_D3 1 CTC_D6 1 CTC_pool* 1 WBC_pool 0 * pool of all CTC
Conclusions: We demonstrate the ability to purify CTC, isolate, and amplify DNA of suitable quality for genetic analysis using a comprehensive targeted sequencing panel. Both known and novel alterations were identified in comparison to research biopsy specimens. This approach allows single cell analysis demonstrating heterogeneity of mutational status in different single cells. Studies of CTC-ESR1 and other genetic abnormalities in patients with known tissue mutations who participated in Mi CTC-ONCOSEQ are now underway.
Citation Format: Paoletti C, Cani AK, Aung K, Darga EP, Cannell EM, Hovelson DH, Yazdani M, Blevins AR, Tokudome N, Larios JM, Thomas DG, Brown ME, Gersch C, Schott AF, Robinson DR, Chinnaiyan AM, Bischoff F, Hayes DF, Rae JM, Tomlins SA. Somatic genetic profiling of circulating tumor cells (CTC) in metastatic breast cancer (MBC) patients. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-02-19.
Collapse
Affiliation(s)
- C Paoletti
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - AK Cani
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - K Aung
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - EP Darga
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - EM Cannell
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - DH Hovelson
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - M Yazdani
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - AR Blevins
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - N Tokudome
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - JM Larios
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - DG Thomas
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - ME Brown
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - C Gersch
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - AF Schott
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - DR Robinson
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - AM Chinnaiyan
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - F Bischoff
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - DF Hayes
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - JM Rae
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - SA Tomlins
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| |
Collapse
|
20
|
Paoletti C, Aung K, Cannell EM, Darga EP, Chu D, Kidwell KM, Thomas DG, Tokudome N, Brown ME, McNutt LM, Gersch C, Schott AF, Park BH, Robinson DR, Chinnaiyan AM, Rae JM, Hayes DF. Abstract P3-05-01: Molecular analysis of cancer tissue, circulating tumor cells (CTC) and cell-free plasma tumor DNA (ptDNA) suggests variable mechanisms of resistance to endocrine therapy (ET) in estrogen receptor (ER) positive metastatic breast cancer (MBC). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-05-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Fifty percent of ER positive MBC patients do not benefit from ET. Potential mechanisms of resistance to ET in this patient population include absence of ER expression by deletion or suppression, alteration in ER signaling pathway genes, or upregulation of multiple growth factor receptor pathways. We hypothesized that genotyping and phenotyping of CTC combined with genomic analysis of ptDNA will provide important insights into the multiple mechanisms of ET resistance and that a set of blood tests might serve as a "liquid biopsy" abrogating the need for tissue specimens.
Methods: Twenty-four patients providing informed consent were enrolled into the Mi CTC-ONCOSEQ study, a companion trial to Mi-ONCOSEQ (the Michigan Oncology Sequencing Program). Seven of these patients (5 with ER immunohistochemistry (IHC) positive and 2 with ER negative cancers) who had available archived primary and metastatic cancer tissue, a research metastatic biopsy for genomic analysis, and who had ≥5CTC/7.5 ml whole blood (WB) characterized for ER protein (CTC-ER) are the focus of this report. All the patients were ET refractory. None of them was progressing on fulvestrant at the time of study entry. CTC enumeration and phenotyping was performed with CellSearch©. Circulating ptDNA was analyzed by droplet digital polymerase chain reaction (ddPCR). ER status from archived tissue was obtained from chart review. ER mRNA expression was determined in the research biopsy of metastatic tissue by using quantitative RNA sequencing. Mutational status of ER gene, ESR1, was determined by Next-gen Sequencing using the Illumina HiSeq 2500 platform.
Results: The 2 control patients with triple negative breast cancer had negative CTC-ER. Discordance between CTC-ER and tissue ER by IHC was observed (Table). Two of the 5 ER positive patients retained CTC-ER positivity (39% and 19% of the CTC). One of them (#7) harbored an ESR1 mutation in the research biopsy tissue and in ptDNA, whereas the other (#14) had wild type (WT) ESR1. CTC-ER protein levels in patients #12, 17 and 24 were negative. All had WT ESR1 in the research biopsy tissue. Of note, patient #12 had WT ESR1 in the research biopsy, but an ESR1 mutation was detected in her ptDNA.
Pt#CTC-ER Tissue-ER ESR1 status in research biopsyESR1 status in ptDNA N[deg]CTC/7.5ml WB% CTC-ER +Primary by IHCMet by IHCMet research biopsy by mRNA 71839%+++Y537SY537S141619%+NA+WTWT12130%+++WTD538G17160%++weakly+WTWT242750%+weakly+weakly+WTWT
Conclusions: These exploratory data suggest heterogeneous mechanisms of resistance to ET in patients with previously determined ER-positive MBC, including ESR1 mutations in ER positive cases (seen in 2 patients) and loss of ER expression (seen in CTC of 3 patients). In contrast, other cancers continue to express WT ESR1, and therefore must have developed alternative mechanisms of resistance. At least 2 of these mechanisms can be detected and monitored with complementary circulating assays: CTC and ptDNA. Further investigations are needed to understand the heterogeneous mechanisms of resistance to ET.
Citation Format: Paoletti C, Aung K, Cannell EM, Darga EP, Chu D, Kidwell KM, Thomas DG, Tokudome N, Brown ME, McNutt LM, Gersch C, Schott AF, Park BH, Robinson DR, Chinnaiyan AM, Rae JM, Hayes DF. Molecular analysis of cancer tissue, circulating tumor cells (CTC) and cell-free plasma tumor DNA (ptDNA) suggests variable mechanisms of resistance to endocrine therapy (ET) in estrogen receptor (ER) positive metastatic breast cancer (MBC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-05-01.
Collapse
Affiliation(s)
- C Paoletti
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - K Aung
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - EM Cannell
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - EP Darga
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - D Chu
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - KM Kidwell
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - DG Thomas
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - N Tokudome
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - ME Brown
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - LM McNutt
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - C Gersch
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - AF Schott
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - BH Park
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - DR Robinson
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - AM Chinnaiyan
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - JM Rae
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - DF Hayes
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| |
Collapse
|
21
|
Sackett SD, Brown ME, Tremmel DM, Ellis T, Burlingham WJ, Odorico JS. Modulation of human allogeneic and syngeneic pluripotent stem cells and immunological implications for transplantation. Transplant Rev (Orlando) 2016; 30:61-70. [PMID: 26970668 DOI: 10.1016/j.trre.2016.02.001] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2015] [Accepted: 02/05/2016] [Indexed: 01/20/2023]
Abstract
Tissues derived from induced pluripotent stem cells (iPSCs) are a promising source of cells for building various regenerative medicine therapies; from simply transplanting cells to reseeding decellularized organs to reconstructing multicellular tissues. Although reprogramming strategies for producing iPSCs have improved, the clinical use of iPSCs is limited by the presence of unique human leukocyte antigen (HLA) genes, the main immunologic barrier to transplantation. In order to overcome the immunological hurdles associated with allogeneic tissues and organs, the generation of patient-histocompatible iPSCs (autologous or HLA-matched cells) provides an attractive platform for personalized medicine. However, concerns have been raised as to the fitness, safety and immunogenicity of iPSC derivatives because of variable differentiation potential of different lines and the identification of genetic and epigenetic aberrations that can occur during the reprogramming process. In addition, significant cost and regulatory barriers may deter commercialization of patient specific therapies in the short-term. Nonetheless, recent studies provide some evidence of immunological benefit for using autologous iPSCs. Yet, more studies are needed to evaluate the immunogenicity of various autologous and allogeneic human iPSC-derived cell types as well as test various methods to abrogate rejection. Here, we present perspectives of using allogeneic vs. autologous iPSCs for transplantation therapies and the advantages and disadvantages of each related to differentiation potential, immunogenicity, genetic stability and tumorigenicity. We also review the current literature on the immunogenicity of syngeneic iPSCs and discuss evidence that questions the feasibility of HLA-matched iPSC banks. Finally, we will discuss emerging methods of abrogating or reducing host immune responses to PSC derivatives.
Collapse
Affiliation(s)
- S D Sackett
- Division of Transplantation, Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA
| | - M E Brown
- Division of Transplantation, Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA
| | - D M Tremmel
- Division of Transplantation, Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA
| | - T Ellis
- Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA
| | - W J Burlingham
- Division of Transplantation, Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA
| | - J S Odorico
- Division of Transplantation, Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
| |
Collapse
|
22
|
Clark RH, Latypov RF, De Imus C, Carter J, Wilson Z, Manchulenko K, Brown ME, Ketchem RR. Remediating agitation-induced antibody aggregation by eradicating exposed hydrophobic motifs. MAbs 2015; 6:1540-50. [PMID: 25484048 PMCID: PMC4622659 DOI: 10.4161/mabs.36252] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Therapeutic antibodies must encompass drug product suitable attributes to be commercially marketed. An undesirable antibody characteristic is the propensity to aggregate. Although there are computational algorithms that predict the propensity of a protein to aggregate from sequence information alone, few consider the relevance of the native structure. The Spatial Aggregation Propensity (SAP) algorithm developed by Chennamsetty et. al. incorporates structural and sequence information to identify motifs that contribute to protein aggregation. We have utilized the algorithm to design variants of a highly aggregation prone IgG2. All variants were tested in a variety of high-throughput, small-scale assays to assess the utility of the method described herein. Many variants exhibited improved aggregation stability whether induced by agitation or thermal stress while still retaining bioactivity.
Collapse
Affiliation(s)
- Rutilio H Clark
- a Department of Therapeutic Discovery; Amgen Inc. ; Thousand Oaks , CA USA
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Yukhymenko-Lescroart MA, Brown ME, Paskus TS. The relationship between ethical and abusive coaching behaviors and student-athlete well-being. ACTA ACUST UNITED AC 2015. [DOI: 10.1037/spy0000023] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
24
|
Paoletti C, Li Y, Muñiz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson V, Irvin WJ, Lin NU, Liu M, Nanda R, Nangia J, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero A, Hayes DF. Abstract P1-04-01: Significance of circulating tumor cells in metastatic triple negative breast cancer: Results of an open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 tigatuzumab (TBCRC 019). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-04-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Circulating Tumor cells (CTCs) are prognostic at baseline and first follow-up in patients with metastatic breast cancer (MBC). Using the most commonly used assay (CellSearch®), we have previously reported the ability to detect apoptotic vs. non-apoptotic CTCs in patients with MBC. However, there has been concern regarding the performance of the CellSearch® assay in patients with triple negative (TN) MBC. We hypothesized that CellSearch® is an effective assay in patients with TN MBC, and that CTC-apoptosis might further separate prognosis. Therefore, we studied CTCs in patients with TN MBC who participated in a prospective randomized phase II trial testing for activity of tigatuzumab (TIG) in combination with nanoparticle albumin-bound paclitaxel (nab-PAC) conducted by the Translational Breast Cancer Research Consortium (overall results reported by Forero A., et al, ASCO 2013).
Methods: Whole blood (WB) was drawn into a CellSave tube at baseline, day 15, and day 29 and CTC counts were determined using the CXC CellSearch® kit. Apoptosis was characterized by staining with a monoclonal antibody that detects a neo-epitope on fragmented cytokeratin (M-30) and independently by visual inspection (nucleic condensation and/or fragmentation, as well as granular cytokeratin). Association between levels of CTCs and CTC-apoptosis with the overall response rate (ORR) and progression free survival (PFS) at baseline, day 15, and day 29 was assessed using logistic regression, Kaplan Meier curves, and Cox proportional hazards modeling.
Results: Of the 60 patients entered into the trial, 52 were evaluable for CTCs. Of these, 19/52 (36.5%), 14/52 (26.9%), and 13/49 (26.5%) had elevated CTCs (≥5CTC/7.5 ml WB) at baseline, day 15, and day 29, respectively. Patients with elevated CTCs at each time point had worse PFS than patients with low or no CTCs. Hazard rates (HR) at baseline, day 15, and day 29 were 2.38 (95% CI: 1.27-4.45, p = 0.007), 2.87 (95% CI: 1.46-5.66, p = 0.002), and 3.40 (95% CI: 1.68-6.89, p = 0.001), respectively. The odds of overall response for those who had elevated CTCs compared to those who did not at baseline, day 15, and day 29, were 0.25 (95% CI: 0.073-0.81, p = 0.024), 0.18 (95% CI: 0.04-0.67, p = 0.014), and 0.06 (95% CI: 0.01-0.28, p = 0.001), respectively. There was no apparent prognostic effect comparing the degree of CTC-apoptosis vs. non-apoptosis.
Conclusions: Similar to observations in other intrinsic subgroups, CTCs were detected in a large fraction of TN MBC patients at baseline using CellSearch® assay, and reductions in CTC levels reflected response. In these homogenously prospectively enrolled TN MBC patients, regardless of treatment, CTCs are prognostic at baseline, day 15, and day 29. It does not appear that analysis of CTC-apoptosis is prognostic.
Supported by Susan G. Komen for the Cure, Veridex, LLC, Fashion Footwear Charitable Foundation of New York/QVC Presents Shoes on Sale™ (DFH), Associazione Sandro Pitigliani and by a studentship from FIRC (CP), Triple Negative Breast Cancer Foundation, The AVON Foundation, and The Breast Cancer Research Foundation.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-04-01.
Collapse
Affiliation(s)
- C Paoletti
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - Y Li
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - MC Muñiz
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - KM Kidwell
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - K Aung
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - DG Thomas
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - ME Brown
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - V Abramson
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - WJ Irvin
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - NU Lin
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - M Liu
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - R Nanda
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - J Nangia
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - AM Storniolo
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - TA Traina
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - C Vaklavas
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - CH Van Poznak
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - AC Wolff
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - A Forero
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - DF Hayes
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| |
Collapse
|
25
|
Paoletti C, Muñiz MC, Aung K, Larios J, Thomas DG, Tokudome N, Brown ME, Connelly MC, Chianese DA, Schott AF, Henry NL, Rae JM, Hayes DF. Abstract PD6-4: Heterogeneity of expression of estrogen receptor by circulating tumor cells suggests diverse mechanisms of resistance to fulvestrant in metastatic breast cancer patients. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-pd6-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Fulvestrant is a selective estrogen receptor down-regulator (SERD). Recent studies have shown that the efficacy of fulvestrant is dose-related. However, at the higher dose (500 mg/month) most cancers develop resistance and progress. We previously reported expression of several markers, including estrogen receptor (ER) and BCL-2, on breast cancer circulating tumor cells (CTC) using CellSearch®. We now report pilot data showing inter-patient heterogeneity of these markers on CTC in patients with known ER positive breast cancer whose disease is progressing on fulvestrant.
Methods: We conducted a pilot trial to determine the analytical validity of measuring expression of markers of endocrine sensitivity (ER, BCL-2) or resistance (HER-2, Ki-67) with fluorescent-labeled antibodies using the CellSearch® system. Patients with ER positive metastatic breast cancer (MBC) whose disease was progressing on any type of therapy were eligible after signed informed consent. This report is limited to the subjects who were progressing on fulvestrant. Whole blood (WB) was characterized for CTC counts and each of the four molecular markers using the CXC CellSearch® kit.
Results: Of 50 enrolled patients, seven were progressing on fulvestrant. Two patients had no detectable CTC, while five patients had an average of ≥5 CTC/7.5 mL WB. Results are shown in a table below:
CTC-ERCTC-BCL-2Patient #Fulvestrant dose (mg/month)Days since last doseN CTC/7.5 mL of WB% of CTC-ER+N CTC/7.5 mL of WB% of CTC-BCL-2+295002880%110%4550028170%170%2250341010%714%850031812%1735%172507728%367%
These exploratory data suggest widely different mechanisms of resistance to fulvestrant in different patients with ER positive MBC. In two of the patients (29, 45) treated with 500 mg/month, both CTC-ER and CTC-BCL-2 expression were absent, suggesting no signaling through the ER pathway. We hypothesize either that fulvestrant was actively down-regulating ER, but the cancers had adopted other growth and survival pathways, or that ER negative, hormone-independent clones had evolved. In the other three cases, ER was clearly present with evidence of signaling, based on BCL-2 expression. Two of these patients (2, 17) were on the lower dose of fulvestrant, now considered to be less effective. However, the third (8) was on the higher dose and yet still had evidence of ER signaling. This observation suggests that some patients may benefit from even higher doses of SERD therapy.
Conclusions: These pilot results suggest heterogeneous biological or pharmacological mechanisms of resistance to SERD therapy. These data suggest that CTC-ER and CTC-BCL-2 expression could serve as pharmacodynamic monitoring tools for dose escalation of fulvestrant or other SERDs. Further molecular analysis might provide biological bases for resistance to fulvestrant.
Supported by Veridex, LLC, Fashion Footwear Charitable Foundation of New York/QVC Presents Shoes on Sale™ (DFH), Associazione Sandro Pitigliani and by a studentship from FIRC (CP).
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr PD6-4.
Collapse
Affiliation(s)
- C Paoletti
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - MC Muñiz
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - K Aung
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - J Larios
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - DG Thomas
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - N Tokudome
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - ME Brown
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - MC Connelly
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - DA Chianese
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - AF Schott
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - NL Henry
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - JM Rae
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - DF Hayes
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| |
Collapse
|
26
|
|
27
|
|
28
|
Schneider T, Graves SDB, Schaller EL, Brown ME. Polar methane accumulation and rainstorms on Titan from simulations of the methane cycle. Nature 2012; 481:58-61. [PMID: 22222747 DOI: 10.1038/nature10666] [Citation(s) in RCA: 103] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2011] [Accepted: 10/20/2011] [Indexed: 11/09/2022]
Abstract
Titan has a methane cycle akin to Earth's water cycle. It has lakes in polar regions, preferentially in the north; dry low latitudes with fluvial features and occasional rainstorms; and tropospheric clouds mainly (so far) in southern middle latitudes and polar regions. Previous models have explained the low-latitude dryness as a result of atmospheric methane transport into middle and high latitudes. Hitherto, no model has explained why lakes are found only in polar regions and preferentially in the north; how low-latitude rainstorms arise; or why clouds cluster in southern middle and high latitudes. Here we report simulations with a three-dimensional atmospheric model coupled to a dynamic surface reservoir of methane. We find that methane is cold-trapped and accumulates in polar regions, preferentially in the north because the northern summer, at aphelion, is longer and has greater net precipitation than the southern summer. The net precipitation in polar regions is balanced in the annual mean by slow along-surface methane transport towards mid-latitudes, and subsequent evaporation. In low latitudes, rare but intense storms occur around the equinoxes, producing enough precipitation to carve surface features. Tropospheric clouds form primarily in middle and high latitudes of the summer hemisphere, which until recently has been the southern hemisphere. We predict that in the northern polar region, prominent clouds will form within about two (Earth) years and lake levels will rise over the next fifteen years.
Collapse
Affiliation(s)
- T Schneider
- California Institute of Technology, Pasadena, California 91125, USA.
| | | | | | | |
Collapse
|
29
|
Paoletti C, Connelly MC, Chianese DA, Brown ME, Muñiz MC, Rae JM, Thomas DG, Hayes DF. P4-07-16: Development of Circulating Tumor Cell-Endocrine Therapy Index in Metastatic Breast Cancer Patients. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-07-16] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Only ∼ 50% of patients (pts) with estrogen receptor (ER) positive metastatic breast cancer (MBC) benefit from endocrine therapy (ET). Currently only clinical judgment can be used to identify pts with endocrine-refractory MBC, who are better palliated with chemotherapy. Circulating Tumor Cells (CTC) are reliably enumerated using an automated immunomagnetic system (CellSearch®; Veridex LLC). High CTC levels predict rapid progression in pts with MBC. We have developed a multi-parameter assay, the CTC-Endocrine Therapy Index (CTC-ETI) using CellSearch® that may identify pts with ER positive MBC who are unlikely to benefit from ET and may be better served with chemotherapy. CTC-ETI scores are assigned based on CTC levels coupled with the relative percent and degree of marker positivity on the CTC. We report preliminary results from a pilot single institutional study.
Methods: CellSearch® has 4 fluorescence channels. Three distinguish CTC from WBC (DAPI, anti-cytokeratin, anti-CD45). The 4th “empty” channel was used to measure ER, BCL-2, HER-2, and Ki-67 expression with fluorescent-labeled antibodies. These 4 markers reflect sensitivity (ER, BCL-2) or resistance (HER-2, Ki-67) to ET. Forty ml of blood was drawn into 4 CellSave® tubes from pts with progressive MBC. Whole blood from 4 tubes was pooled and divided into 4 different 7.5 ml aliquots of blood, which were processed and characterized for CTC counts and each of the four molecular markers using the CXC CellSearch® kit.
Results: 21 pts have been accrued to the feasibility study. One patient was ineligible. Five of 20 pts had low CTC counts (<5 CTC/7.5ml whole blood), and are expected to have a relatively favorable prognosis. CTC-ETI was successfully determined in 10 pts (50%): 2 pts had low, while 3 had intermediate, and 5 had high CTC-ETI. Technical difficulties precluded accurate CTC-ETI in the remaining 5 patients. Of note, expression of the biomarkers among CTC in single patients was heterogeneous, suggesting that future iterations of the CTC-ETI will have to consider expression variability. Further exploratory results regarding associations between CTC-ETI and outcomes will be presented.
Conclusions: ER, BCL-2, HER-2, and Ki-67 can be accurately determined on CTC using the 4th channel in the CellSearch® system to calculate CTC-ETI. We predict that lower CTC-ETI scores (low or no CTC, or CTC with high CTC ER and BCL-2 and low CTC HER-2 and Ki-67) could be associated with favorable response to ET. Successful completion of the feasibility study will lead to a prospective trial to determine if high CTC-ETI at baseline predicts resistance and rapid progression on ET in women starting a new endocrine therapy for MBC.
Supported by Veridex, LLC, Fashion Footwear Charitable Foundation of New York/QVC Presents Shoes on Sale ™ (DFH), Associazione Sandro Pitigliani and by a studentship from FIRC (CP).
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-07-16.
Collapse
Affiliation(s)
- C Paoletti
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - MC Connelly
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - DA Chianese
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - ME Brown
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - MC Muñiz
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - JM Rae
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - DG Thomas
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - DF Hayes
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| |
Collapse
|
30
|
Abstract
Abstract
A range of factors was established, such as knowledge and ethics, which underlay the practice of six groups of health professionals: pharmacists, dentists, doctors, nurses, optometrists and radiographers. These factors have been identified as “concepts”. The method used was content analysis of official documents of the professions, such as codes of ethics and guidance documents. Postal questionnaires were also used to collect data. Nine principal concepts were identified. A “collective professional consciousness” was evident, in which knowledge, patient welfare and ethics were important concepts for the highest quality of practice. The perceived importance of these and other concepts was broadly similar across the professions.
Collapse
Affiliation(s)
- M E Brown
- Great Yarmouth and Waveney health authority
| | - S Ellis
- East Anglian regional health authority
| | - P A Linley
- Pharmacy Practice Research Unit, University of Bradford
| | - T G Booth
- Pharmacy Practice Research Unit, University of Bradford
| |
Collapse
|
31
|
Brown ME, Ellis S, Linley PA, Booth TG. Professional values and pharmacy practice: implications of a predominantly female Register of Pharmaceutical Chemists. International Journal of Pharmacy Practice 2011. [DOI: 10.1111/j.2042-7174.1992.tb00563.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Abstract
It is expected that the Register of Pharmaceutical Chemists of Great Britain will comprise a majority of female practitioners by about the year 2000. It is, therefore, pertinent to compare the opinions of male and female practitioners (pharmacists, doctors, dentists, nurses, optometrists and radiographers) about their practice. This study uses methodology published in an earlier paper to identify those opinions. Male and female practitioners had similar views in three areas: the concepts they considered important for the highest quality of practice, their valuation of patient safety, and the prevalence of conflict between National Health Service policies and professional ideas. There were three concepts which female practitioners considered more important than did males. One was confidentiality. Another was law (and, indeed, more male, than female, pharmacists were both investigated by the Royal Pharmaceutical Society's Statutory Committee and removed from the Register). The third was “health care art”: a new balance between the artistic and scientific sides of pharmacy is predicted when the majority of pharmacists are female. The one concept which male practitioners considered more important was independence. This may be related to the lower proportion of females than males who have risen to positions of authority.
Collapse
Affiliation(s)
- M E Brown
- Great Yarmouth and Waveney health authority
| | - S Ellis
- East Anglian regional health authority
| | - P A Linley
- School of Pharmacy, University of Bradford
| | - T G Booth
- Pharmacy Practice Research Unit, University of Bradford
| |
Collapse
|
32
|
Brown ME, Martin JR, Rosenbluth J, Ariel M. A novel path for rapid transverse communication of vestibular signals in turtle cerebellum. J Neurophysiol 2010; 105:1071-88. [PMID: 21178000 DOI: 10.1152/jn.00986.2009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Voltage-sensitive dye activity within the thin, unfoliated turtle cerebellar cortex (Cb) was recorded in vitro during eighth cranial nerve (nVIII) stimulation. Short latency responses were localized to the middle of the lateral edges of both ipsilateral and contralateral Cb [vestibulocerebellum (vCb)]. Even with a severed contralateral Cb peduncle, stimulation of the nVIII ipsilateral to the intact peduncle evoked contralateral vCb responses with a mean latency of only 0.25 ms after the ipsilateral responses, even though the distance between them was ∼ 5 mm. We investigated whether a rapidly conducting commissure exists between each vCb by stimulating one of them directly. Responses in both vCb spread sagittally, but, surprisingly, there was no sequential activation along a transverse Cb beam between them. In contrast, stimulation medial to either vCb evoked transverse beams that required ∼ 20 ms to cross the Cb. Therefore, the rapid commissural connection between each vCb is not mediated by slowly conducting parallel fibers. Also, the vCb was not strongly activated by climbing fiber stimulation, suggesting that inputs to vCb involve distinct cerebellar circuits. Responses between the two vCb remained following knife cuts through the rostral and caudal Cb along the midline, through both peduncles, and even shallow midline cuts to the middle Cb through its white matter and granule cell layer. Commissural responses were still observed only with a narrow transverse bridge between each vCb or in thick transverse Cb slices. Horseradish peroxidase transport from one vCb labeled transverse axons traveling within the Purkinje cell layer that were larger than parallel fibers and lacked varicosities. In sagittal sections, cross-section profiles of myelinated axons were observed around Purkinje cells midway between the rostral and caudal Cb. This novel pathway for transverse communication between lateral edges of turtle Cb suggests that afferents may directly conduct vestibular information rapidly across the Cb to coordinate vestibulomotor reflex behaviors.
Collapse
Affiliation(s)
- Michael E Brown
- Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, St. Louis, Missouri, USA
| | | | | | | |
Collapse
|
33
|
Ariel M, Brown ME. Origin and timing of voltage-sensitive dye signals within layers of the turtle cerebellar cortex. Brain Res 2010; 1357:26-40. [PMID: 20707989 DOI: 10.1016/j.brainres.2010.08.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2010] [Revised: 08/04/2010] [Accepted: 08/04/2010] [Indexed: 11/16/2022]
Abstract
Optical recording techniques were applied to the turtle cerebellum to localize synchronous responses to microstimulation of its cortical layers and reveal the cerebellum's three-dimensional processing. The in vitro yet intact cerebellum was first immersed in voltage-sensitive dye and its responses while intact were compared to those measured in thick cerebellar slices. Each slice is stained throughout its depth, even though the pial half appeared darker during epi-illumination and lighter during trans-illumination. Optical responses were shown to be mediated by the voltage-sensitive dye because the evoked signals had opposite polarity for 540- and 710-nm light, but no response to 850-nm light. Molecular layer stimulation of the intact cerebellum evoked slow transverse beams. Similar beams were observed in the molecular layer of thick transverse slices but not sagittal slices. With low currents, beams in transverse slices were restricted to sublayers within the molecular layer, conducting slowly away from the stimulus site. These excitatory beams were observed nearly all the way across the turtle cerebellum, distances of 4-6mm. Microstimulation of the granule cell layer of both transverse or sagittal slices evoked a local membrane depolarization restricted to a radial wedge, but these radial responses did not activate measurable molecular layer beams in transverse slices. White matter microstimulation in sagittal slices (near the ventricular surface of the turtle cerebellum) activated the granule cell and Purkinje cell layers, but not the molecular layer. These responses were nearly synchronous, were primarily caudal to the stimulation, and were blocked by cobalt ions. Therefore, synaptic responses in all cerebellar layers contribute to optical signals recorded in intact cerebellum in vitro (Brown and Ariel, 2009). Rapid radial signaling connects a sagittally-oriented, fast-conduction system of the deep layers with the transverse-oriented, slow-conducting molecular layer, thereby permitting complex temporal processing between two tangential but orthogonal paths in the cerebellar cortex.
Collapse
Affiliation(s)
- Michael Ariel
- Department of Pharmacological & Physiological Science, Saint Louis University School of Medicine, Saint Louis, MO 63104, USA.
| | | |
Collapse
|
34
|
Abstract
In a field study, the authors investigated the relationship between socialized charismatic leadership and values congruence between leaders and followers. Socialized charismatic leadership theory holds that charismatic leaders convey a values-based message and bring about values congruence between themselves and their followers. Yet, other research suggests that individuals' values are stable and closely linked to occupational membership and that employees' values are therefore likely to be quite difficult to change. Results of this study suggest that occupations are indeed associated with multiple types of employee values. The results also demonstrate that, for 3 of the 4 values studied, socialized charismatic leadership is associated with values congruence between the specific values leaders say they transmit to their followers and the values their followers say they use in work. The findings shed additional light on the values alignment process. Implications for research and practice are discussed.
Collapse
Affiliation(s)
- Michael E Brown
- Sam and Irene Black School of Business, Pennsylvania State University-Erie, Erie, PA 16563-1400, USA.
| | | |
Collapse
|
35
|
Santos RP, Prestidge CB, Brown ME, Urbancyzk B, Murphey DK, Salvatore CM, Jafri HS, McCracken GH, Ahmad N, Sanchez PJ, Siegel JD. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis. Pediatr Pulmonol 2009; 44:148-54. [PMID: 19137597 DOI: 10.1002/ppul.20966] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
UNLABELLED Alternative antimicrobial regimens are needed for treatment of methicillin-resistant Staphylococcus aureus (MRSA)-associated pulmonary exacerbations in children with cystic fibrosis (CF). There are no published pharmacokinetic (PK) and pharmacodynamic (PD) data for linezolid in children with CF. OBJECTIVES (1) To determine the PK and PD profile of linezolid among children with CF; (2) to characterize the effect of linezolid on MRSA infection; (3) to determine the effect of age and CF transmembrane regulator (CFTR) gene mutations on drug clearance. HYPOTHESES Linezolid clearance is enhanced in children with CF requiring a higher dosage regimen. Age and CFTR gene mutations affect drug clearance. METHODS This was a retrospective cohort study; medical records of children with MRSA-associated pulmonary exacerbations treated with linezolid (10 mg/kg/dose IV every 8h) were reviewed. Linezolid peak and trough concentrations in serum were determined by high performance liquid chromatography, PK profiles determined using standard noncompartmental method, and PD indices were evaluated. RESULTS 10 children (mean +/- SD, 10.2 +/- 5.5 years) received 14 courses of linezolid at 10 +/- 0.4 mg/kg/dose every 8h for 15.4 +/- 3.2 days. Seven had homozygous DeltaF508 CFTR mutation. Peak and trough linezolid concentrations varied widely (range, 8.4-20.5 and 0.1-11.5 mcg/mL respectively). The PK profile of children <10 years differed significantly from older patients (>or=10 years). The PK indices of children with homozygous DeltaF508 differed marginally from those with heterozygous CFTR mutations, but there were too few subjects to allow separation of age and CFTR mutations effect. No patient achieved the target PD ratio of AUC/MIC >80. MRSA persisted in sputum or throat culture after treatment with linezolid. CONCLUSIONS Additional PK and PD data are needed to optimize linezolid therapy in children with cystic fibrosis; it is likely that higher doses will be needed.
Collapse
Affiliation(s)
- Roberto P Santos
- Division of Infectious Diseases, Department of Pediatrics, University of Texas Southwestern Medical Center Dallas, Dallas, Texas, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
Physiological activity of the turtle cerebellar cortex (Cb), maintained in vitro, was recorded during microstimulation of inferior olive (IO). Previous single-electrode responses to such stimulation showed similar latencies across a limited region of Cb, yet those recordings lacked spatial and temporal resolution and the recording depth was variable. The topography and timing of those responses were reexamined using photodiode optical recordings. Because turtle Cb is thin and unfoliated, its entire surface can be stained by a voltage-sensitive dye and transilluminated to measure changes in its local absorbance. Microstimulation of the IO evoked widespread depolarization from the rostral to the caudal edge of the contralateral Cb. The time course of responses measured at a single photodiode matched that of single-microelectrode responses in the corresponding Cb locus. The largest and most readily evoked response was a sagittal band centered about 0.7 mm from the midline. Focal white-matter (WM) microstimulation on the ventricular surface also activated sagittal bands, whereas stimulation of adjacent granule cells evoked a radial patch of activation. In contrast, molecular-layer (ML) microstimulation evoked transverse beams of activation, centered on the rostrocaudal stimulus position, which traveled bidirectionally across the midline to the lateral edges of the Cb. A timing analysis demonstrated that both IO and WM microstimulation evoked responses with a nearly simultaneous onset along a sagittal band, whereas ML microstimulation evoked a slowly propagating wave traveling about 25 cm/s. The response similarity to IO and WM microstimulation suggests that the responses to WM microstimulation are dominated by activation of its climbing fibers. The Cb's role in the generation of precise motor control may result from these temporal and topographic differences in orthogonally oriented pathways. Optical recordings of the turtle's thin flat Cb can provide insights into that role.
Collapse
Affiliation(s)
- Michael E Brown
- Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, St. Louis, MO, USA
| | | |
Collapse
|
37
|
Boyce JP, Brown ME, Chin W, Fitzner JN, Paxton RJ, Shen M, Stevens T, Wolfson MF, Wright CD. Identification of 14−3−3ζ by Chemical Affinity with Salicylanilide Inhibitors of Interleukin-12p40 Production. Bioconjug Chem 2008; 19:1775-84. [PMID: 18763820 DOI: 10.1021/bc800078q] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Jim P. Boyce
- Amgen Incorporated, 1201 Amgen Court West, Seattle, Washington 98119
| | - Michael E. Brown
- Amgen Incorporated, 1201 Amgen Court West, Seattle, Washington 98119
| | - Wilson Chin
- Amgen Incorporated, 1201 Amgen Court West, Seattle, Washington 98119
| | | | - Raymond J. Paxton
- Amgen Incorporated, 1201 Amgen Court West, Seattle, Washington 98119
| | - Min Shen
- Amgen Incorporated, 1201 Amgen Court West, Seattle, Washington 98119
| | - Tracey Stevens
- Amgen Incorporated, 1201 Amgen Court West, Seattle, Washington 98119
| | - Martin F. Wolfson
- Amgen Incorporated, 1201 Amgen Court West, Seattle, Washington 98119
| | | |
Collapse
|
38
|
Brown ME, Fitzner JN, Stevens T, Chin W, Wright CD, Boyce JP. Salicylanilides: selective inhibitors of interleukin-12p40 production. Bioorg Med Chem 2008; 16:8760-4. [PMID: 18715785 DOI: 10.1016/j.bmc.2008.07.024] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2008] [Revised: 06/30/2008] [Accepted: 07/14/2008] [Indexed: 10/21/2022]
Abstract
Interleukin (IL)-12p40, a subunit component of both IL-12 and IL-23, is being widely studied for its role in inflammatory disease. As part of an effort to profile cellular signaling pathways across different cell types, we report salicylanilide inhibitors of IL-12p40 production in stimulated dendritic cells. Based on a hypothesis that a desirable therapeutic profile is one that could block IL-12p40 but not IL-6 production, we engaged in directed analoging. This resulted in salicylanilides with similar IL-12p40 related potency but enhanced selectivity relative to IL-6 production.
Collapse
Affiliation(s)
- Michael E Brown
- Medicinal Chemistry, Amgen Inc., 1201 Amgen Court West, Seattle, WA 98119, USA
| | | | | | | | | | | |
Collapse
|
39
|
Abstract
Of the many types of biomolecules used for molecular imprinting applications, proteins are some of the most useful, yet challenging, templates to work with. One method, termed the 'epitope approach', involves imprinting a short peptide fragment of the protein into the polymer to promote specific adsorption of the entire protein, similar to the way an antigen binds to an antibody via the epitope. Whole lysozyme or the 16 residue lysozyme C peptide was imprinted into porous silica scaffolds using sol-gel processing. After removing template, scaffolds were exposed to lysozyme and/or RNase A, which was used as a competitor molecule of comparable size. When comparing protein- to peptide-imprinted scaffolds, similar amounts of lysozyme and RNase were bound from single protein solutions. However, while whole lysozyme-imprinted scaffolds showed about 4:1 preferential binding of lysozyme to RNase, peptide-imprinted scaffolds failed to show statistical significance, even though a slight preferential binding trend was present. These initial studies suggest there is potential for using peptide-imprinting to create specific protein-binding sites on porous inorganic surfaces, although further development of the materials is needed.
Collapse
Affiliation(s)
- M E Brown
- Center for Biomedical Engineering, University of Kentucky, Lexington, KY 40506
| | | |
Collapse
|
40
|
Abstract
The discovery of dwarf planet Eris was followed shortly by the discovery of its satellite, Dysnomia, but the satellite orbit, and thus the system mass, was not known. New observations with the Keck Observatory and the Hubble Space Telescopes show that Dysnomia has a circular orbit with a radius of 37,350 +/- 140 (1-sigma) kilometers and a 15.774 +/- 0.002 day orbital period around Eris. These orbital parameters agree with expectations for a satellite formed out of the orbiting debris left from a giant impact. The mass of Eris from these orbital parameters is 1.67 x 10(22) +/- 0.02 x 10(22) kilograms, or 1.27 +/- 0.02 that of Pluto.
Collapse
Affiliation(s)
- Michael E Brown
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | | |
Collapse
|
41
|
|
42
|
Brown ME, Barkume KM, Ragozzine D, Schaller EL. A collisional family of icy objects in the Kuiper belt. Nature 2007; 446:294-6. [PMID: 17361177 DOI: 10.1038/nature05619] [Citation(s) in RCA: 164] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2006] [Accepted: 01/19/2007] [Indexed: 11/08/2022]
Abstract
The small bodies in the Solar System are thought to have been highly affected by collisions and erosion. In the asteroid belt, direct evidence of the effects of large collisions can be seen in the existence of separate families of asteroids--a family consists of many asteroids with similar orbits and, frequently, similar surface properties, with each family being the remnant of a single catastrophic impact. In the region beyond Neptune, in contrast, no collisionally created families have hitherto been found. The third largest known Kuiper belt object, 2003 EL61, however, is thought to have experienced a giant impact that created its multiple satellite system, stripped away much of an overlying ice mantle, and left it with a rapid rotation. Here we report the discovery of a family of Kuiper belt objects with surface properties and orbits that are nearly identical to those of 2003 EL61. This family appears to be fragments of the ejected ice mantle of 2003 EL61.
Collapse
Affiliation(s)
- Michael E Brown
- Division of Geological and Planetary Sciences, California Institute of Technology, Mail Code 150-21, 1200 E. California Blvd, Pasadena, California 91125, USA.
| | | | | | | |
Collapse
|
43
|
|
44
|
Chung H, Dudley M, Brown ME, Hollingsworth MD. Synchrotron White Beam X-Ray Topography Characterization of Defect Structures in 2,10-Undecanedione/Urea Inclusion Compounds. ACTA ACUST UNITED AC 2006. [DOI: 10.1080/10587259608039378] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Hua Chung
- a Dept. of Materials Science & Engineering , SUNY at Stony Brook, Stony Brook , NY , 11794-2275 , USA
| | - Michael Dudley
- a Dept. of Materials Science & Engineering , SUNY at Stony Brook, Stony Brook , NY , 11794-2275 , USA
| | - Michael E. Brown
- b Dept. of Chemistry , Indiana University , Bloomington , IN , 47405 , USA
| | | |
Collapse
|
45
|
Abstract
The authors conducted a field study to investigate the relationship between socialized charismatic leadership and deviance in work groups. Because socialized charismatic leaders are thought to play an ethical leadership role, the authors hypothesized that the socialized charismatic leadership style would be associated with reduced deviance in the leader's work group. This prediction was supported for both the interpersonal and the organizational dimensions of deviance. Next, the authors examined the mediating role of values congruence. The results were partially supportive of the values congruence mediating hypothesis. Implications for future research and for management are discussed.
Collapse
Affiliation(s)
- Michael E Brown
- Sam and Irene Black School of Business, Pennsylvania State University, Erie, PA 16563-1400, USA.
| | | |
Collapse
|
46
|
de Pater I, Ádámkovics M, Bouchez AH, Brown ME, Gibbard SG, Marchis F, Roe HG, Schaller EL, Young E. Titan imagery with Keck adaptive optics during and after probe entry. ACTA ACUST UNITED AC 2006. [DOI: 10.1029/2005je002620] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
47
|
Abstract
Observations of Titan's mid-latitude clouds from the W. M. Keck and Gemini Observatories show that they cluster near 350 degrees W longitude, 40 degrees S latitude. These clouds cannot be explained by a seasonal shift in global circulation and thus presumably reflect a mechanism on Titan such as geysering or cryovolcanism in this region. The rate of volatile release necessary to trigger cloud formation could easily supply enough methane to balance the loss to photolysis in the upper atmosphere.
Collapse
Affiliation(s)
- Henry G Roe
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA.
| | | | | | | | | |
Collapse
|
48
|
Barnes JW, Brown RH, Turtle EP, McEwen AS, Lorenz RD, Janssen M, Schaller EL, Brown ME, Buratti BJ, Sotin C, Griffith C, Clark R, Perry J, Fussner S, Barbara J, West R, Elachi C, Bouchez AH, Roe HG, Baines KH, Bellucci G, Bibring JP, Capaccioni F, Cerroni P, Combes M, Coradini A, Cruikshank DP, Drossart P, Formisano V, Jaumann R, Langevin Y, Matson DL, McCord TB, Nicholson PD, Sicardy B. A 5-micron-bright spot on Titan: evidence for surface diversity. Science 2005; 310:92-5. [PMID: 16210535 DOI: 10.1126/science.1117075] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Observations from the Cassini Visual and Infrared Mapping Spectrometer show an anomalously bright spot on Titan located at 80 degrees W and 20 degrees S. This area is bright in reflected light at all observed wavelengths, but is most noticeable at 5 microns. The spot is associated with a surface albedo feature identified in images taken by the Cassini Imaging Science Subsystem. We discuss various hypotheses about the source of the spot, reaching the conclusion that the spot is probably due to variation in surface composition, perhaps associated with recent geophysical phenomena.
Collapse
Affiliation(s)
- Jason W Barnes
- Lunar and Planetary Laboratory, University of Arizona, Tucson, AZ 85721, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
West RA, Brown ME, Salinas SV, Bouchez AH, Roe HG. No oceans on Titan from the absence of a near-infrared specular reflection. Nature 2005; 436:670-2. [PMID: 16079839 DOI: 10.1038/nature03824] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2005] [Accepted: 05/18/2005] [Indexed: 11/08/2022]
Abstract
With its substantial atmosphere of nitrogen, hydrocarbons and nitriles, Saturn's moon Titan is a unique planetary satellite. Photochemical processing of the gaseous constituents produces an extended haze that obscures the surface. Soon after the Voyager fly-bys in 1980 and 1981 photochemical models led to the conclusion that there should be enough liquid methane/ethane/nitrogen to cover the surface to a depth of several hundred metres. Recent Earth-based radar echoes imply that surface liquid may be present at a significant fraction of the locations sampled. Here we present ground-based observations (at near-infrared wavelengths) and calculations showing that there is no evidence thus far for surface liquid. Combined with the specular signatures from radar observations, we infer mechanisms that produce very flat solid surfaces, involving a substance that was liquid in the past but is not in liquid form at the locations we studied.
Collapse
Affiliation(s)
- R A West
- MS 169-237 Jet Propulsion Laboratory, 4800 Oak Grove Drive, Pasadena, California 91109, USA.
| | | | | | | | | |
Collapse
|
50
|
Abstract
Development of the nervous system requires remarkable changes in cell structure that are dependent upon the cytoskeleton. The importance of specific components of the neuronal cytoskeleton, such as microtubules and neurofilaments, to neuronal function and development has been well established. Recently, increasing focus has been put on understanding the functional role of the actin cytoskeleton in neurons. Important modulators of the actin cytoskeleton are the large family of myosins, many of which (classes I, II, III, V, VI, VII, IX, and XV; Fig. 1) are expressed in developing neurons or sensory cells. Myosins are force-producing proteins that have been implicated in a wide variety of cellular functions in the developing nervous system, including neuronal migration, process outgrowth, and growth cone motility, as well as other aspects of morphogenesis, axonal transport, and synaptic and sensory functions. We review the roles that neuronal myosins play in these functions with particular focus on the first three events listed above, as well as sensory function.
Collapse
Affiliation(s)
- Michael E Brown
- Department of Anatomy and Neurobiology, Washington University School of Medicine, Box 8108, 660 S. Euclid Avenue, St. Louis, Missouri 63110, USA
| | | |
Collapse
|